Abstract:The epidermal growth factor receptor (EGFR) serves as an attractive target for cancer molecular imaging and therapy. Our previous positron emission tomography (PET) studies showed that the EGFR-targeting affibody molecules Cu-64-DOTA-ZEGFR:1907 and F-18-FBEM-ZEGFR:1907 can discriminate between high and low EGFR-expression tumors and have the potential for patient selection for EGFR-targeted therapy. Compared with Cu-64, F-18 may improve imaging of EGFR-expression and is more suitable for clinical application, but the labeling reaction of F-18-FBEM-ZEGFR:1907 requires a long synthesis time. The aim of the present study is to develop a new generation of F-18 labeled affibody probes ((AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907) and to determine whether they are suitable agents for imaging of EGFR expression. The first approach consisted of conjugating ZEGFR:1907 with NOTA and radiolabeling with (AlF)-F-18 to produce (AlF)-F-18-NOTA-ZEGFR:1907. In a second approach the prosthetic group F-18-labeled-2-cyanobenzothiazole (F-18-CBT) was conjugated to Cys-ZEGFR:1907 to produce F-18-CBT-ZEGFR:1907. Binding affinity and specificity of (AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907 to EGFR were evaluated using A431 cells. Biodistribution and PET studies were conducted on mice bearing A431 xenografts after injection of (AlF)-F-18-NOTA-ZEGFR:1907 or F-18-CBT-ZEGFR:1907 with or without coinjection of unlabeled affibody proteins. The radiosyntheses of (AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907 were completed successfully within 40 and 120 min with a decay-corrected yield of 15% and 41% using a 2-step, 1-pot reaction and 2-step, 2-pot reaction, respectively. Both probes bound to EGFR with low nanomolar affinity in A431 cells. Although F-18-CBT-ZEGFR:1907 showed instability in vivo, biodistribution studies revealed rapid and high tumor accumulation and quick clearance from normal tissues except the bones. In contrast, (AlF)-F-18-NOTA-ZEGFR:1907 demonstrated high in vitro and in vivo stability, high tumor uptake, and relative low uptake in most of the normal organs except the liver and kidneys at 3 h after injection. The specificity of both probes for A431 tumors was confirmed by their lower uptake on coinjection of unlabeled affibody. PET studies showed that (AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907 could clearly identify EGFR positive tumors with good contrast. Two strategies for F-18-labeling of affibody molecules were successfully developed as two model platforms using NOTA or CBT coupling to affibody molecules that contain an N-terminal cysteine. (AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907 can be reliably obtained in a relatively short time. Biodistribution and PET studies demonstrated that (AlF)-F-18-NOTA-ZEGFR:1907 is a promising PET probe for imaging EGFR expression in living mice.

Further Characterization of the Epidermal Growth Factor Receptor Ligand 11C-PD153035

Assessment of<sup>11</sup>C-labeled-4-<i>N</i>-(3-bromoanilino)-6, 7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression

Molecular imaging of epidermal growth factor receptor in glioma-bearing rats]

A Pilot Study on EGFR-Targeted Molecular Imaging of PET/CT With C-11-PD153035 in Human Gliomas

Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Positive Tumor with a 64cu Labeled Affibody Protein

Affibody Molecule for Positron Emission Tomography Imaging of Human Epidermal Growth Factor Receptor: Validation in Mouse Models and Human Cancer Tissues

Metabolism of Epidermal Growth Factor Receptor Targeting Probe [11C]PD153035: Impact on Biodistribution and Tumor Uptake in Rats

A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas.

PET of EGFR Expression with an 18F-Labeled Affibody Molecule

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Imaging a Pancreatic Carcinoma Xenograft Model with 11C-Acetate: a Comparison Study with 18F-FDG

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor

Biodistribution in Healthy KM Mice and Micro PET/CT Imaging in U87MG Tumor-Bearing Nude Mice of a New 18F-Labeled Cyclic RGD Dimer

Pharmacokinetic analysis of 6-O-[18F]FEE for PET imaging of EGFR mutation

PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.

Preclinical PET Imaging of EGFR Levels: Pairing a Targeting with a Non-Targeting Sel-tagged Affibody-based Tracer to Estimate the Specific Uptake

Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.

Tracing Investigation of Targeting Gastric Cancer with 18F Labeled Anti-Human Epidermal Growth Factor Receptor 2 Specific Affibody Molecule ZHER2:342

A NIR-II Fluorescent Probe for High Contrast Non-Invasive Imaging of Tumors with a High EGFR-expression

MicroPET imaging studies of 89Zr-labeled EGFR and HER2 antibodies in gastric mucinous adenocarcinoma